General Information
Drug ID
DR00683
Drug Name
Buspirone
Synonyms
8-(4-(4-(2-Pyrimidinyl)-1-piperizinyl)butyl)-8-azaspiro(4,5)decane-7,9-dione; 8-[4-(4-Pyrimidin-2-yl-piperazin-1-yl)-butyl]-8-aza-spiro[4.5]decane-7,9-dione; 8-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione; 8-{4-[4-(pyrimidin-2-yl)piperazin-1-yl]butyl}-8-azaspiro[4.5]decane-7,9-dione; Ansial; Ansial (TN); Ansiced; Ansiced (TN); Anxiron; Anxiron (TN); Axoren; Axoren (TN); Bespar; Bespar (TN); BuSpar (TN); Buspimen (TN); Buspinol (TN); Buspiron (TN); Buspirona; Buspirona [INN-Spanish]; Buspirone (INN); Buspirone [INN:BAN]; Buspirone-MDTS; Buspironum; Buspironum [INN-Latin]; Buspisal; Buspisal (TN); Gen-Buspirone; Gen-Buspirone (TN); MJ-9022-1; N-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-1-cyclopentanediacetamide; Narol (TN); Sorbon (TN); Spamilan (TN); Spitomin (TN)
Drug Type
Small molecular drug
Therapeutic Class
Antianxiety Agents
Structure
3D MOL 2D MOL
Formula
C21H31N5O2
Canonical SMILES
C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4
InChI
InChI=1S/C21H31N5O2/c27-18-16-21(6-1-2-7-21)17-19(28)26(18)11-4-3-10-24-12-14-25(15-13-24)20-22-8-5-9-23-20/h5,8-9H,1-4,6-7,10-17H2
InChIKey
QWCRAEMEVRGPNT-UHFFFAOYSA-N
CAS Number
CAS 36505-84-7
Pharmaceutical Properties Molecular Weight 385.5 Topological Polar Surface Area 69.6
Heavy Atom Count 28 Rotatable Bond Count 6
Hydrogen Bond Donor Count 0 Hydrogen Bond Acceptor Count 6
XLogP
2.6
PubChem CID
2477
PubChem SID
103166970 ,103916226 ,10589701 ,11110857 ,11112732 ,11113821 ,11336096 ,11361335 ,11364650 ,11367212 ,11369774 ,11377936 ,11462307 ,11466397 ,11467517 ,11486154 ,11495570 ,11533496 ,14902734 ,24714738 ,25671043 ,26751994 ,29221641 ,46508113 ,4652644 ,47365265 ,47365266 ,47440338 ,47589062 ,47662354 ,48259310 ,48259311 ,48259312 ,48415667 ,49698848 ,49872682 ,50104669 ,51066541 ,51091905 ,53790629 ,57321342 ,7978828 ,8151653 ,85209802 ,85787807 ,85788842 ,90340780 ,9079 ,92309215 ,93166677
ChEBI ID
ChEBI:3223
TTD Drug ID
D0U2OO

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.